Andrew M. Saidel

President & Chief Executive Officer

Mr. Saidel has worked with senior corporate executives and policy makers on business, regulatory, and legislative issues for nearly two decades. He speaks and reads Japanese fluently and lived in Japan for five years. He has assisted many Fortune 500 companies to create stronger markets for their technologies and services, develop collaborative coalitions with stakeholders, and resolve complex policy challenges. He is a registered securities Principal and holds the U.S. Financial Industry Regulatory Authority Series 24 and 7 Licenses.

Mr. Saidel is a member of the Board of Directors of RaQualia Pharma Inc., a drug discovery and development company based in Nagoya, Japan. He is Executive Vice President and Partner of Sage Canyon Advisors, LLC, a middle market investment bank specializing in mergers and acquisitions.

Prior to co-founding DSA, Mr. Saidel worked for three years as a policy aide to 21 members of Japan’s ruling Liberal Democratic Party, and then for three years as an Analyst for the U.S. Government in Washington. He has spoken on business and public policy at seminars hosted by the Japanese Cabinet Office, the U.S. National Intelligence Council, the Department of State, the National Institutes of Health, the World Affairs Council, AARP, and the Advanced Medical Technology Association.

Mr. Saidel serves as a member of the International Collaboration Advisory Council at The University of Tokyo, a panel of faculty members and outside advisors assisting the university with international development strategy. He earned a B.A. from Colgate University, a Certificate with Honors from Kansai University of Foreign Studies in Osaka, Japan, and an A.M. from the Center for East Asian Studies at Stanford University.